GT Biopharma (GTBP) Requests Withdrawal of Form S-1 Registration Statement

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (“NK”) cell engager platform, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-284032) that it filed with the SEC originally on December 23, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company’s common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.

You May Also Be Interested In

• Sunshine Biopharma sets up $4M at-the-market stock offering
• Centuri acquires J.J. White to expand industrial services
• ServisFirst Bancshares announces 2-for-1 stock split in August